

RESUMEN

En este trabajo de tesis se ha investigado la relación de las enzimas esfingosina quinasa 1 (SphK1) y hemoxigenasa 1 (HO-1) con el cáncer. En el caso de la primera de estas enzimas se ha podido demostrar que se encuentra sobre expresada en carcinomas escamosos de cabeza y cuello y que su presencia se correlaciona con una menor sobrevida de los pacientes. Se ha aportado evidencia indicando que dicha correlación puede ser la manifestación de una relación de causa y efecto en la que esta quinasa estimula la proliferación celular disminuyendo los niveles de p21^{Cip1}, e inhibe la apoptosis al disminuir los niveles de caspasa 3 clivada e incrementar los de p-Bad.

En cuanto a HO-1 se ha explorado su relación con el cáncer en el carcinoma escamoso de cabeza y cuello y en cáncer de pulmón y de mama, tanto en tumores humanos como en modelos animales.

En carcinomas escamosos de cabeza y cuello se ha demostrado que HO-1 se encuentra sobre expresada y que se correlaciona con el grado tumoral. Se ha comprobado que la enzima presenta localización nuclear además de su típica localización citoplasmática, que dicha localización es mayor en las células tumorales que en los tejidos epiteliales adyacentes y que se correlaciona con tumores más agresivos y de peor pronóstico y con la progresión tumoral.

En cáncer de pulmón HO-1 se detectó en las células epiteliales del tumor mostrando una localización principalmente citoplasmática en comparación con tejidos pulmonares de aspecto normal donde los niveles de expresión fueron menores y con localización nuclear más frecuente. También se observó que se correlacionaba con estadios más avanzados de la enfermedad, con el tamaño tumoral y con la presencia de metástasis ganglionares.

En cáncer de mama se han realizado por primera vez estudios de expresión de HO-1 en tumores humanos comprobándose que se correlaciona con una mayor sobrevida de los pacientes. Se ha identificado un modelo animal adecuado para estudiar la relación de la enzima con este tipo de cáncer. Utilizando este modelo se ha comprobado que la activación de la misma conduce a un menor desarrollo tumoral. Se ha aportado evidencia indicando que los mecanismos que conducen a esta disminución del volumen tumoral, y tal vez también a la mayor sobrevida global de los pacientes, son la disminución en la

supervivencia celular, debida a un efecto pro apoptótico, y la inhibición de la migración celular producidas por esta enzima. También se ha comprobado en este carcinoma la localización nuclear de la enzima y se ha aportado evidencia indicando que una forma truncada en el extremo carboxilo terminal se localiza en el núcleo. Esta localización nuclear no se correlaciona con la sobrevida global de los pacientes.

Finalmente, los resultados obtenidos en esta tesis sugieren que ambas enzimas pueden ser de potencial interés como factores pronósticos y/o blancos terapéuticos y señalan la necesidad de continuar investigando los mecanismos celulares y moleculares que la desregulación de estas enzimas podría estar afectando contribuyendo así al desarrollo del cáncer.

ABSTRACT

In this thesis the relation between the enzymes sphingosine kinase 1 and heme oxygenase 1 with cancer has been investigated. In the case of the former one it has been demonstrated that it is over expressed in head neck squamous cell carcinoma and that its presence correlates with a shorter patient survival. Evidence has been provided showing that such correlation could be due to a cause-effect relationship in which this kinase stimulates cellular proliferation by down regulation of p21^{Cip1} levels and inhibits apoptosis through a decrease in the levels of cleaved caspase 3 and an increase in p-Bad.

Regarding heme oxygenase 1, its relation with cancer has been investigated in head neck squamous cell carcinoma, lung and breast cancer both in human tumors and animal models.

In head and neck squamous cell carcinoma the enzyme was shown to be over expressed and to correlate with tumor grade. Furthermore, nuclear localization of the enzyme has also been demonstrated. It has also been detected that such nuclear localization is more frequent in tumor cells than in adjacent non malignant tissues. Furthermore this nuclear localization correlates with lower differentiation grades and with tumor progression.

In lung cancer the heme oxygenase 1 has been detected mainly in the cytoplasm of epithelial cells whereas it was more frequently localized in the nucleus in normal lung tissues. Additionally, enzyme levels have been demonstrated to be higher in tumor tissues than in non malignant adjacent ones and to correlate with advanced stages of the disease, with tumor size and with lymph node metastasis.

This is the first study showing heme oxygenase 1 protein expression in human breast tumor tissues and its correlation with longer patient survival. This research has also identified an adequate animal model to study the relation between the enzyme and this type of cancer. In this animal model the enzyme activation leads to a decrease in tumor burden. Evidence has also been provided showing that the mechanisms responsible for this decrease in the tumor volume are the reduction in cellular survival due to a pro apoptotic effect and the inhibition of cellular migration. A nuclear localization of the enzyme in this tumor type has also been demonstrated. Evidence has also been provided

that this nuclear heme oxygenase 1 is a C-terminal truncated protein. This nuclear localization does not correlate with patient survival.

Finally, the results obtained in this thesis suggest that both enzymes could be potentially interesting as prognostic factors and/or therapeutic targets and they encourage future investigations regarding the cellular and molecular mechanisms modulated by these enzymes and whose deregulation could contribute to cancer development.

Referencias

Abraham NG, Lin JH, Dunn MW, Schwartzman ML. 1987. Presence of heme oxygenase and NADPH cytochrome P-450 (c) reductase in human corneal epithelium. *Invest Ophthalmol Vis Sci.* 28(9):1464-72.

Agüero MF, Facchinetti MM, Sheleg Z, Senderowicz AM. 2005. Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. *Cancer Res.* 65(8):3364-73.

Akao Y, Banno Y, Nakagawa Y, Hasegawa N, Kim TJ, Murate T, Igarashi Y, Nozawa Y. 2006. High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation. *Biochem Biophys Res Commun.* 342(4):1284-90.

Alam J, Shibahara S, Smith A. 1989. Transcriptional activation of the heme oxygenase gene by heme and cadmium in mouse hepatoma cells. *J Biol Chem.* 264(11):6371-5.

Alaoui-Jamali MA, Bismar TA, Gupta A, Szarek WA, Su J, Song W, Xu Y, Xu B, Liu G, Vlahakis JZ, Roman G, Jiao J, Schipper HM. 2009. A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer. *Cancer Res.* 69(20):8017-24.

Alberts B, Johnson A, Lewis J, Raft M, Roberts K, Walter P. 2002. *Molecular Biology of The Cell.* Cuarta Edición. Garland Sciences.

Andersen MH, Sørensen RB, Brimnes MK, Svane IM, Becker JC, thor Straten P. 2009. Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. *J Clin Invest.* 119(8):2245-56.

Andreadi CK, Howells LM, Atherfold PA, Manson MM. 2006. Involvement of Nrf2, p38, B-Raf, and nuclear factor-kappaB, but not phosphatidylinositol 3-kinase, in induction of hemeoxygenase-1 by dietary polyphenols. *Mol Pharmacol.* 69(3):1033-40.

Anisimov VN, Ukraintseva SV, Yashin AI. 2005. Cancer in rodents: does it tell us about cancer in humans? *Nat Rev Cancer.* 5(10):807-19.

Becker JC, Fukui H, Imai Y, Sekikawa A, Kimura T, Yamagishi H, Yoshitake N, Pohle T, Domschke W, Fujimori T. 2007. Colonic expression of heme

oxygenase-1 is associated with a better long-term survival in patients with colorectal cancer. *Scand. J. Gastroenterol.* 42 (7):852-8.

Bektas M, Orfanos CE, Geilen CC. 2000. Different vitamin D analogues induce sphingomyelin hydrolysis and apoptosis in the human keratinocytes cell line HACaT. *Cell Mol. Biol. (Noisy-le-grand)*. 46 (1):111-9.

Berberat PO, Dambrauskas Z, Gulbinas A, Giese T, Giese N, Künzli B, Autschbach F, Meuer S, Büchler MW, Friess H. 2005. Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. *Clin Cancer Res.* 11(10):3790-8.

Boschetto P, Zeni E, Mazzetti L, Miotto D, Lo Cascio N, Maestrelli P, Marian E, Querzoli P, Pedriali M, Murer B, De Rosa E, Fabbri LM, Mapp CE. 2008. Decreased heme-oxygenase (HO)-1 in the macrophages of non-small cell lung cancer. *Lung Cancer.* 59(2):192-7.

Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem.* 72:248-54.

Brinkmann OA, Roigas J, Hertle L. 2002. Systemic immunotherapy of metastatic renal cell carcinoma and long-term outcome. *Urologe A.* 41(3):231-8.

Brown NS, Bicknell R. 2001. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. *Breast Cancer Res.* 3(5):323-7.

Bukholm IK, Nesland JM, Kåresen R, Jacobsen U, Børresen-Dale AL. 1997. Interaction between bcl-2 and p21 (WAF1/CIP1) in breast carcinomas with wild-type p53. *Int J Cancer.* 73(1):38-41.

Burdick AD, Davis JW 2nd, Liu KJ, Hudson LG, Shi H, Monske ML, Burchiel SW. 2003. Benzo(α)pyrene quinones increase cell proliferation, generate reactive oxygen species, and transactivate the epidermal growth factor receptor in breast epithelial cells. *Cancer Res.* 63(22):7825-33.

Busserolles J, Megías J, Terencio MC, Alcaraz MJ. 2006. Heme oxygenase-1 inhibits apoptosis in Caco-2 cells via activation of Akt pathway. *Int J Biochem Cell Biol.* 38(9):1510-7.

Caltabiano MM, Poste G, Greig RG. 1988. Induction of the 32-kD human stress protein by auranofin and related triethylphosphine gold analogs. *Biochem Pharmacol.* 37(21):4089-93.

Cancer. Principles and Practice of Oncology, De Vita VT, Hellman S, Rosenberg SA, Lippincott Williams & Wilkins, 6th edición, 2001

Carnevale RP, Proietti CJ, Salatino M, Urtreger A, Peluffo G, Edwards DP, Boonyaratanakornkit V, Charreau EH, Bal de Kier Joffé E, Schillaci R, Elizalde PV. 2007. Progesterone effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. *Mol Endocrinol.* 21(6):1335-58.

Chang KW, Lee TC, Yeh WI, Chung MY, Liu CJ, Chi LY, Lin SC. 2004. Polymorphism in heme oxygenase-1 (HO-1) promoter is related to the risk of oral squamous cell carcinoma occurring on male areca chewers. *Br J Cancer.* 91 (8):1551-5.

Chen GG, Liu ZM, Vlantis AC, Tse GM, Leung BC, van Hasselt CA. 2004. Heme oxygenase-1 protects against apoptosis induced by tumor necrosis factor-alpha and cycloheximide in papillary thyroid carcinoma cells. *J Cell Biochem.* 92(6):1246-56.

Cianfrocca M, Gradishar W. 2009. New molecular classifications of breast cancer. *CA Cancer J Clin.* 59(5):303-13.

Cruse I, Maines MD. 1988. Evidence suggesting that the two forms of heme oxygenase are products of different genes. *J Biol Chem.* 263(7):3348-53.

Curino A, Patel V, Nielsen BS, Iskander AJ, Ensley JF, Yoo GH, Holsinger FC, Myers JN, El-Nagaar A, Kellman RM, Shillitoe EJ, Molinolo AA, Gutkind JS, Bugge TH. 2004. Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography. *Oral Oncol.* 40(10):1026-32.

Curino AC, Engelholm LH, Yamada SS, Holmbeck K, Lund LR, Molinolo AA, Behrendt N, Nielsen BS, Bugge TH. 2005. Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy. *J Cell Biol.* 169(6):977-85.

Cuvillier O, Levade T. 2001. Sphingosine 1-phosphate antagonizes apoptosis of human leukemia cells by inhibiting release of cytochrome c and Smac/DIABLO from mitochondria. *Blood.* 98(9):2828-36.

Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S, Spiegel S. 1996. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. *Nature.* 381 (6585):800-3

Cuvillier O, Rosenthal DS, Smulson ME, Spiegel S. 1998. Sphingosine 1-phosphate inhibits activation of caspases that cleave poly(ADP-ribose) polymerase and lamins during Fas- and ceramide-mediated apoptosis in Jurkat T lymphocytes. *J Biol Chem.* 273(5):2910-6.

De Matteis F, Dawson SJ, Pons N, Pipino S. 2002. Bilirubin and uroporphyrinogen oxidation by induced cytochrome P4501A and cytochrome P4502B. Role of polyhalogenated biphenyls of different configuration. *Biochem Pharmacol.* 63(4):615-24.

De Palma G, Mozzoni P, Acampa O, Internullo E, Carbognani P, Rusca M, Goldoni M, Corradi M, Tiseo M, Apostoli P, Mutti A. 2010. Expression levels of some antioxidant and epidermal growth factor receptor genes in patients with early-stage non-small cell lung cancer. *J Nucleic Acids.* pii: 147528.

Deininger MH, Meyermann R, Trautmann K, Duffner F, Grote EH, Wickboldt J, Schluesener HJ. 2000. Heme oxygenase (HO)-1 expressing macrophages/microglial cells accumulates during oligodendroglioma progression. *Brain Res.* 882 (1-2):1-8.

Delon C, Manifava M, Wood E, Thompson D, Krugmann S, Pyne S, Ktistakis NT. 2004. Sphingosine kinase 1 is an intracellular effector of phosphatidic acid. *J Biol Chem.* 279(43):44763-74.

Deshane J, Chen S, Caballero S, Grochot-Przeczek A, Was H, Li Calzi S, Lach R, Hock TD, Chen B, Hill-Kapturczak N, Siegal GP, Dulak J, Jozkowicz A, Grant MB, Agarwal A. 2007. Stromal cell-derived factor 1 promotes angiogenesis via a heme oxygenase 1-dependent mechanism. *J Exp Med.* 204(3):605-18.

Dhakshinamoorthy S, Jain AK, Bloom DA, Jaiswal AK. 2005. Bach1 competes with Nrf2 leading to negative regulation of the antioxidant response element (ARE)-mediated NAD(P)H:quinone oxidoreductase 1 gene expression and induction in response to antioxidants. *J Biol Chem.* 280(17):16891-900.

Doi K, Akaike T, Fujii S, Tanaka S, Ikebe N, Beppu T, Shibahara S, Ogawa M, Maeda H. 1999. Induction of haem oxygenase-1 nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth. *Br J Cancer.* 80(12):1945-54.

Donati C, Nincheri P, Cencetti F, Rapizzi E, Farnararo M, Bruni P. 2007. Tumor necrosis factor-alpha exerts pro-myogenic action in C2C12 myoblasts via sphingosine kinase/S1P2 signaling. *FEBS Lett.* 581(23):4384-8.

Duda DG, Cohen KS, di Tomaso E, Au P, Klein RJ, Scadden DT, Willett CG, Jain RK. 2006. Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial

and progenitor cells as biomarkers for antiangiogenic therapy. *J Clin Oncol.* 24(9):1449-53.

Facchinetti MM, Beuret C, Marquez MG, Sterin Speziale N. 2003. Differential branching of the sphingolipid metabolic pathways with the stage of development. Involvement of sphingosine kinase. *Biol Neonate* 84 (3): 243-51.

Facchinetti MM, De Siervi A, Toskos D, Senderowicz AM. 2004. UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway. *Cancer Res.* 64(10):3629-37.

Facchinetti MM, Gandini NA, Fermento ME, Sterin-Speziale NB, Ji Y, Patel V, Gutkind JS, Rivadulla MG, Curino AC. 2010. The expression of sphingosine kinase-1 in head and neck carcinoma. *Cells Tissues Organs.*192(5):314-24.

Facchinetti MM, Leocata Nieto F, Márquez MG, Sterin-Speziale N. 2008. Stratification of sphingosine kinase-1 expression and activity in rat kidney. *Cells Tissues Organs.*188(4):384-92.

Fang J, Akaike T, Maeda H. 2004. Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment. *Apoptosis.* 9(1):27-35.

Fang J, Sawa T, Akaike T, Akuta T, Sahoo SK, Khaled G, Hamada A, Maeda H. 2003. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. *Cancer Res.* 63 (13):3567-74.

Fillies T, Woltering M, Brandt B, Van Diest JP, Werkmeister R, Joos U, Buerger H. 2007. Cell cycle regulating proteins p21 and p27 in prognosis of oral squamous cell carcinomas. *Oncol Rep.* 17 (2):355-9.

Foresti R, Clark JE, Green CJ, Motterlini R. 1997. Thiol compounds interact with nitric oxide in regulating heme oxygenase-1 induction in endothelial cells. Involvement of superoxide and peroxynitrite anions. *J Biol Chem.* 272(29):18411-7.

Fredenburgh LE, Perrella MA, Mitsialis A. 2007. The role of Heme-Oxygenase-1 in pulmonary disease. *Am J Respir Cell Mol Biol.* 36:158-65.

French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK, Smith CD. 2003. Discovery and evaluation of inhibitors of human sphingosine kinase. *Cancer Res.* 63 (18):5962-9.

French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK, Smith CD. 2006. Antitumor activity of sphingosine kinase inhibitors. *J Pharmacol Exp Ther.* 318(2):596-603.

Fujita H, Yamamoto M, Yamagami T, Hayashi N, Bishop TR, De Verneuil H, Yoshinaga T, Shibahara S, Morimoto R, Sassa S. 1991. Sequential activation of genes for heme pathway enzymes during erythroid differentiation of mouse Friend virus-transformed erythroleukemia cells. *Biochim Biophys Acta.* 1090(3):311-6.

Fukuda Y, Aoyama Y, Wada A, Igarashi Y. 2004. Identification of PECAM-1 association with sphingosine kinase 1 and its regulation by agonist-induced phosphorylation. *Biochim Biophys Acta.* 1636(1):12-21.

Fukushima N, Ishii I, Contos JJ, Weiner JA, Chun J. 2001. Lysophospholipid receptors. *Annu Rev Pharmacol Toxicol.* 41:507-34.

Futerman AH, Hannun YA. 2004. The complex life of simple sphingolipids. *EMBO Rep.* 5 (8): 777-82.

Gamble JR, Xia P, Hahn CN, Drew JJ, Drogemuller CJ, Brown D, Vadas MA. 2006. Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumor effects. *Int. J. Cancer.* 118 (10):2412-20.

Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, Gerthoffer WT, Bamberg JR, English D. 2001. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. *J Clin Invest.* 108(5):689-701.

Giordano A, Nisoli E, Tonello C, Canello R, Carruba MO, Cinti S. 2000. Expression and distribution of heme oxygenase-1 and 2 in rat Brown adipose tissue: the modulatory role of the noradrenergic system. *FEBS Lett.* 487 (2):171-5.

Gomez DE, Alonso DF. 1998. *Introducción a la oncología molecular.* Universidad Nacional de Quilmes. Primera Edición.

Goodman AI, Choudhury M, da Silva JL, Jiang S, Abraham NG. 1996. Quantitative measurement of heme oxygenase-1 in the human renal adenocarcinoma. *J Cell Biochem.* 63(3):342-8.

Goodman AI, Choudhury M, da Silva JL, Schwartzman ML, Abraham NG. 1997. Overexpression of the heme oxygenase gene in renal cell carcinoma. *Proc. Soc. Exp. Biol. Med.* 214 (1):54-61.

Gorgoulis V, Zoumpourlis V, Rassidakis G, Karameris A, Barbatis C, Spandidos DA, Kittas C. 1995. Molecular analysis of p53 gene in laryngeal premalignant and malignant lesions. p53 protein immunohistochemical expression is positively related to proliferating cell nuclear antigen labelling index. *Virchows Arch.*426(4):339-44.

Graham BL, Mink JT, Cotton DJ. 1983. Dynamic measurements of CO diffusing capacity using discrete samples of alveolar gas. *J Appl Physiol.* 54(1):73-9.

Gueron G, De Siervi A, Ferrando M, Salierno M, De Luca P, Elguero B, Meiss R, Navone N, Vazquez ES. 2009. Critical role of endogenous heme oxygenase 1 as a tuner of the invasive potential of prostate cancer cells. *Mol Cancer Res.* 7 (11):1745-55.

Guy CT, Cardiff RD, Muller WJ. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. *Mol Cell Biol.* 12(3):954-61.

Hahn WC, Weinberg RA. 2002. Modelling the molecular circuitry of cancer. *Nat Rev Cancer.*2(5):331-41.

Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S. 2006. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. *Biochim Biophys Acta.* 1758(12):2016-26.

Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. *Cell.* 100(1):57-70.

Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. *Cell.* 144(5):646-74.

Hannun YA, Luberto C. 2004. Lipid metabolism: ceramide transfer protein adds a new dimension. *Curr Biol.* 14(4):R163-5.

Hara E, Takahashi K, Tominaga T, Kumabe T, Kayama T, Suzuki H, Fujita H, Yoshimoto T, Shirato K, Shibahara S. 1996. Expression of heme oxygenase and inducible nitric oxide synthase mRNA in human brain tumors. *Biochem Biophys Res Commun.* 224(1):153-8.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr; American Society of Clinical Oncology. 2007. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. *J Clin Oncol.* 25(33):5287-312.

Hayashi S, Omata Y, Sakamoto H, Higashimoto Y, Hara T, Sagara Y, Noguchi M. 2004. Characterization of rat heme oxygenase-3 gene. Implication of

processed pseudogenes derived from heme oxygenase-2 gene. *Gene*. 336(2):241-50.

Hayes DF. 2010. Contribution of biomarkers to personalized medicine. *Breast Cancer Res*. 12 Suppl 4:S3.

Heffernan-Stroud LA, Obeid LM. 2011. p53 and regulation of bioactive sphingolipids. *Adv Enzyme Regul*. 51(1):219-28.

Herzinger T, Kleuser B, Schäfer-Korting M, Korting HC. 2007. Sphingosine-1-phosphate signaling and the skin. *Am J Clin Dermatol*. 8 (6):329-36.

Higo M, Uzawa K, Kawata T, Kato Y, Kouzu Y, Yamamoto N, Shibahara T, Mizoe JE, Ito H, tsujii H, Tanzawa H. 2006. Enhancement of SPHK1 in vitro by carbon ion irradiation in oral squamous cell carcinoma. *Int J Radiat Oncol Biol Phys*. 65:867-75.

Hill M, Pereira V, Chauveau C, Zagani R, Remy S, Tesson L, Mazal D, Ubillos L, Brion R, Asghar K, Mashreghi MF, Kotsch K, Moffett J, Doebis C, Seifert M, Boczkowski J, Osinaga E, Anegon I. 2005. Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase. *FASEB J*. 19 (14):1957-68.

Hillen F, Griffioen AW. 2007. Tumour vascularization: sprouting angiogenesis and beyond. *Cancer Metastasis Rev*. 26(3-4):489-502.

Hirai K, Sasahira T, Ohmori H, Fujii K, Kuniyasu H. 2007. Inhibition of heme oxygenase-1 by zinc protoporphyrin IX reduces tumor growth of LL/2 lung cancer in C57BL mice. *Int J Cancer*. 120(3):500-5.

Hirschberg CB, Kisic A, Schroepfer GJ Jr. 1970. Enzymatic formation of dihydro sphingosine 1-phosphate. *J Biol Chem*. 245(12):3084-90.

Hiwasa T, Sakiyama S. 1986. Increase in the synthesis of a Mr 32,000 protein in BALB/c 3T3 cells after treatment with tumor promoters, chemical carcinogens, metal salts, and heat shock. *Cancer Res*. 46(5):2474-81.

Hla T, Maciag T. 1990. An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors. *J Biol Chem*. 265(16):9308-13.

Ho JW, Man K, Sun CK, Lee TK, Poon RT, Fan ST. 2005. Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. *Mol Cancer Ther*. 4(9):1430-8.

Hong CC, Ambrosone CB, Ahn J, Choi JY, McCullough ML, Stevens VL, Rodriguez C, Thun MJ, Calle EE. 2007. Genetic variability in iron-related

oxidative stress pathways (Nrf2, NQO1, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer. *Cancer Epidemiol Biomarkers Prev.* 16(9):1784-94.

Hori R, Kashiba M, Toma T, Yachie A, Goda N, Makino N, Soejima A, Horiguchi N, Takayama H, Toyoda M, Otsuka T, Fukusato T, Merlino G, Takagi H, Mori M. 2002. Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. *Oncogene.* 21(12):1791-9.

Hu JL, Li ZY, Liu W, Zhang RG, Li GL, Wang T, Ren JH, Wu G. 2010. Polymorphism in heme oxygenase-1 (HO-1) promoter and alcohol are related to the risk of esophageal squamous cell carcinoma on Chinese males. *Neoplasma.* 57(1):86-92.

Inagaki Y, Li PY, Wada A, Mitsutake S, Igarashi Y. 2003. Identification of functional nuclear export sequences in human sphingosine kinase 1. *Biochem Biophys Res Commun.* 311(1):168-73.

Ishikawa T, Yoshida N, Higashihara H, Inoue M, Uchiyama K, Takagi T, Handa O, Kokura S, Naito Y, Okanoue T, Yoshikawa T. 2003. Different effects of constitutive nitric oxide synthase and heme oxygenase on pulmonary or liver metastasis of colon cancer in mice. *Clin Exp Metastasis.* 20(5):445-50.

Iwasa H, Han J, Ishikawa F. 2003. Mitogen-activated protein kinase p38 defines the common senescence-signalling pathway. *Genes Cells.* 8(2):131-44.

Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, Wingo PA, Howe HL, Anderson RN, Edwards BK. 2004. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. *Cancer.* 101 (1):3-27.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. 2007. Cancer statistics, 2007. *CA Cancer J Clin.* 57(1):43-66.

Johnson KR, Becker KP, Facchinetti MM, Hannun YA, Obeid LM. 2002. PKC-dependent activation of sphingosine kinase 1 and translocation to the plasma membrane. Extracellular release of sphingosine-1-phosphate induced by phorbol 12-myristate 13-acetate (PMA). *J Biol Chem.* 277 (38):35257-62.

Johnson KR, Johnson KY, Crellin HG, Ogretmen B, Boylan AM, Harley RA, Obeid LM. 2005. Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. *J. Histochem. Cytochem.* 53 (9):1159-66.

Jozkowicz A, Huk I, Nigisch A, Weigel G, Dietrich W, Motterlini R, Dulak J. 2003. Heme oxygenase and angiogenic activity of endothelial cells: stimulation

by carbon monoxide and inhibition by tin protoporphyrin-IX. *Antioxid Redox Signal*. 5(2):155-62.

Jozkowicz A, Was H, Dulak J. 2007. Heme oxygenase-1 in tumors: is it a false friend?. *Antioxid Redox Signal*. 9(12):2099-117.

Kampa M, Alexaki VI, Notas G, Nifli AP, Nistikaki A, Hatzoglou A, Bakogeorgou E, Kouimtoglou E, Blekas G, Boskou D, Gravanis A, Castanas E. 2004. Antiproliferative and apoptotic effects of selective phenolic acids on T47D human breast cancer cells: potential mechanisms of action. *Breast Cancer Res*. 6(2):R63-74.

Kapitonov D, Allegood JC, Mitchell C, Hait NC, Almenara JA, Adams JK, Zipkin RE, Dent P, Kordula T, Milstien S, Spiegel S. 2009. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. *Cancer Res*. 69(17):6915-23.

Kapranos N, Stathopoulos GP, Manolopoulos L, Kokka E, Papadimitriou C, Bibas A, Yiotakis J, Adamopoulos G. 2001. p53, p21 and p27 protein expression in head and neck cancer and their prognostic value. *Anticancer Res*. 21 (81B):521-8.

Kapturczak MH, Wasserfall C, Brusko T, Campbell-Thompson M, Ellis TM, Atkinson MA, Agarwal A. 2004. Heme oxygenase-1 modulates early inflammatory responses: evidence from the heme oxygenase-1-deficient mouse. *Am J Pathol*. 165(3):1045-53.

Karahatay S, Thomas K, Koybasi S, Senkal CE, Elojeimy S, Liu X, Bielawski J, Day TA, Gillespie MB, Sinha D, Norris JS, Hannun YA, Ogretmen B. 2007. Clinical relevance of ceramide metabolism in the pathogenesis of human head and neck squamous cell carcinoma (HNSCC): attenuation of C(18)-ceramide in HNSCC tumors correlates with lymphovascular invasion and nodal metastasis. *Cancer Lett*. 256 (1):101-11.

Kawamori T, Osta W, Johnson KR, Pettus BJ, Bielawski J, Tanaka T, Wargovich MJ, Reddy BS, Hannun YA, Obeid LM, Zhou D. 2006. Sphingosine kinase 1 is up regulated in colon carcinogenesis. *FASEB J*. 20 (2):386-8.

Keyse SM, Tyrrell RM. 1987. Both near ultraviolet radiation and the oxidizing agent hydrogen peroxide induce a 32-kDa stress protein in normal human skin fibroblasts. *J Biol Chem*. 262(30):14821-5.

Keyse SM, Tyrrell RM. 1989. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. *Proc Natl Acad Sci U S A*. 86(1):99-103.

Kikuchi A, Yamaya M, Suzuki S, Yasuda H, Kubo H, Nakayama K, Handa M, Sasaki T, Shibahara S, Sekizawa K, Sasaki H. 2005. Association of susceptibility to the development of lung adenocarcinoma with the heme oxygenase-1 gene promoter polymorphism. *Hum Genet.* 116(5):354-60.

Kikuchi G, Yoshida T, Noguchi M. 2005. Heme oxygenase and heme degradation. *Biochem Biophys Res Commun.* 338 (1):558-67.

Kim DH, Kim JH, Kim EH, Na HK, Cha YN, Chung JH, Surh YJ. 2009. 15-Deoxy-Delta12,14-prostaglandin J2 upregulates the expression of heme oxygenase-1 and subsequently matrix metalloproteinase-1 in human breast cancer cells: possible roles of iron and ROS. *Carcinogenesis.* 30(4):645-54.

Kim HP, Wang X, Nakao A, Kim SI, Murase N, Choi ME, Ryter SW, Choi AM. 2005. Caveolin-1 expression by means of p38beta mitogen-activated protein kinase mediates the antiproliferative effect of carbon monoxide. *Proc. Natl. Acad. Sci. U.S.A.* 102 (32):11319-24.

Kim HR, Kim S, Kim EJ, Park JH, Yang SH, Jeong ET, Park C, Youn MJ, So HS, Park R. 2008. Suppression of Nrf2-driven heme oxygenase-1 enhances the chemosensitivity of lung cancer A549 cells toward cisplatin. *Lung Cancer.* 60(1):47-56.

Kimpara T, Takeda A, Watanabe K, Itoyama Y, Ikawa S, Watanabe M, Arai H, Sasaki H, Higuchi S, Okita N, Takase S, Saito H, Takahashi K, Shibahara S. 1997. Microsatellite polymorphism in the human heme oxygenase-1 gene promoter and its application in association studies with Alzheimer and Parkinson disease. *Hum Genet.* 100(1):145-7.

Kleuser B, Maceyka M, Milstien S, Spiegel S. 2001. Stimulation of nuclear sphingosine kinase activity by platelet-derived growth factor. *FEBS Lett.* 503(1):85-90.

Kocanova S, Buytaert E, Matroule JY, Piette J, Golab J, de Witte P, Agostinis P. 2007. Induction of heme-oxygenase 1 requires the p38MAPK and PI3K pathways and suppresses apoptotic cell death following hypericin-mediated photodynamic therapy. *Apoptosis.* 12 (4):731-41.

Kohama T, Olivera A, Edsall L, Nagiec MM, Dickson R, Spiegel S. 1998. Molecular cloning and functional characterization of murine sphingosine kinase. *J Biol Chem.* 273(37):23722-8.

Kohno M, Momoi M, Oo ML, Paik JH, Lee YM, Venkataraman K, Ai Y, Ristimaki AP, Fyrst H, Sano H, Rosenberg D, Saba JD, Proia RL, Hla T. 2006. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. *Mol Cell Biol.* 26(19):7211-23.

Koybasi S, Senkal CE, Sundararai K, Spassieva S, Bielawski J, Osta W, Day TA, Jiang JC, Jazwinski SM, Hannun YA, Obeid LM, Ogretmen B. 2004. Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene in human head and neck squamous cell carcinomas. *J. Biol Chem.* 279 (43):44311-9.

Kuroda H, Takeno M, Murakami S, Miyazawa N, Kaneko T, Ishigatsubo Y. 2010. Inhibition of heme oxygenase-1 with an epidermal growth factor receptor inhibitor and cisplatin decreases proliferation of lung cancer A549 cells. *Lung Cancer.* 67(1):31-6.

La P, Fernando AP, Wang Z, Salahudeen A, Yang G, Lin Q, Wright CJ, Dennery PA. 2009. Zinc protoporphyrin regulates cyclin D1 expression independent of heme oxygenase inhibition. *J Biol Chem.* 284(52):36302-11.

Lacaná E, Maceyka M, Milstien S, Spiegel S. 2002. Cloning and characterization of a protein kinase A anchoring protein (AKAP)-related protein that interacts with and regulates sphingosine kinase 1 activity. *J Biol Chem.* 277(36):32947-53.

Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature.* 227(5259):680-5.

Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottellet M, Nong Y, Wen D, Adams J, Dang L, Staudt LM. 2005. Small molecule inhibitors of I κ B kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. *Clin Cancer Res.* 11(1):28-40.

Laura EA, González MS, Vacchino M. 2009. Incidencia de cáncer en la Región Sanitaria I de la Provincia de Buenos Aires durante el período 1998 al 2002. Asociación Argentina de Prevención y Educación del Cáncer. Hospital Interzonal Dr. José Penna – Unidad de Investigación Biomédica.

Lavrovsky Y, Schwartzman ML, Levere RD, Kappas A, Abraham NG. 1994. Identification of binding sites for transcription factors NF- κ B and AP-2 in the promoter region of the human heme oxygenase 1 gene. *Proc Natl Acad Sci U S A.* 91(13):5987-91.

Le Scolan E, Pchejetski D, Banno Y, Denis N, Mayeux P, Vainchenker W, Levade T, Moreau-Gachelin F. 2005. Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. *Blood.* 106(5):1808-16.

Leclercq TM, Pitson SM. 2006. Cellular signalling by sphingosine kinase and sphingosine 1-phosphate. *IUBMB Life.* 58 (8):467-72.

Lee J, Lee SK, Lee BU, Lee HJ, Cho NP, Yoon JH, Choi HR, Lee SK, Kim EC. 2008. Upregulation of heme oxygenase-1 in oral epithelial dysplasias. *Int J Oral Maxillofac Surg.* 37(3):287-92.

Lee MJ, Van Brocklyn JR, Thangada CH, Liu AR, Hand R, Menzeleev R, Spiegel S, Hla T. 1998. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. *Science.* 279:1552-55.

Lee PJ, Alam J, Wiegand GW, Choi AM. 1996. Overexpression of heme oxygenase-1 in human pulmonary epithelial cells results in cell growth arrest and increased resistance to hyperoxia. *Proc Natl Acad Sci U S A.* 93(19):10393-8.

Lee SK, Park DY, Lee HJ, Lee J, Choi MK, Jeon BH, Jun CD, Lee SK, Kim EC. 2007. Functional interaction between nitric oxide-induced iron homeostasis and heme oxygenase-1 in immortalized and malignant oral keratinocytes. *Cancer Lett.* 249(2):283-93.

Lee SS, Yang SF, Tsai CH, Chou MC, Chou MY, Chang YC. 2008. Upregulation of heme oxygenase-1 expression in areca-quid-chewing-associated oral squamous cell carcinoma. *J Formos Med Assoc.* 107(5):355-63.

Lee TS, Chau LY. 2002. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. *Nat Med.* 8(3):240-6.

Li CQ, Kim MY, Godoy LC, Thiantanawat A, Trudel LJ, Wogan GN. 2009. Nitric oxide activation of Keap1/Nrf2 signaling in human colon carcinoma cells. *Proc Natl Acad Sci U S A.* 106(34):14547-51.

Li J, Guan HY, Gong LY, Song LB, Zhang N, Wu J, Yuan J, Zheng YJ, Huang ZS, Li M. 2008. Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. *Clin Cancer Res.* 14(21):6996-7003.

Li M, Li Z, Sun X, Yang L, Fang P, Liu Y, Li W, Xu J, Lu J, Xie M, Zhang D. 2010. Heme oxygenase-1/p21WAF1 mediates peroxisome proliferator-activated receptor-gamma signaling inhibition of proliferation of rat pulmonary artery smooth muscle cells. *FEBS J.* 277(6):1543-50.

Li MY, Yip J, Hsin MK, Mok TS, Wu Y, Underwood MJ, Chen GG. 2008. Haem oxygenase-1 plays a central role in NNK-mediated lung carcinogenesis. *Eur Respir J.* 32(4):911-23.

Li Volti G, Ientile R, Abraham NG, Vanella A, Cannavò G, Mazza F, Currò M, Raciti G, Avola R, Campisi A. 2004. Immunocytochemical localization and expression of heme oxygenase-1 in primary astroglial cell culture during

differentiation: effect of glutamate. *Biochem Biophys Res Commun.* 315 (2):517-24.

Li W, Thompson CH, O'Brien CJ, McNeil EB, Scolyer RA, Cossart YE, Veness MJ, Walker DM, Morgen GJ, Rose BR. 2003. Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. *Int. J. Cancer.* 106:553-8.

Liefers GJ, Tollenaar RA. 2002. Cancer genetics and their application to individualised medicine. *Eur J Cancer.* 38(7):872-9.

Limaye V, Li X, Hahn C, Xia P, Berndt MC, Vadas MA, Gamble JR. 2005. Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1-dependent activation of PI-3K/Akt and regulation of Bcl-2 family members. *Blood.* 105(8):3169-77.

Lin CW, Shen SC, Hou WC, Yang LY, Chen YC. 2008. Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase-9. *Mol Cancer Ther.* 7(5):1195-206.

Lin EY, Pollard JW. 2004. Macrophages: modulators of breast cancer progression. *Novartis Found Symp.* 256:158-68; discussion 168-72, 259-69.

Lin Q, Weis S, Yang G, Weng YH, Helston R, Rish K, Smith A, Bordner J, Polte T, Gaunitz F, Dennery PA. 2007. Heme oxygenase-1 protein localizes to the nucleus and activates transcription factors important in oxidative stress. *J. Biol. Chem.* 282 (28):20621-33.

Lin SC, Liu CJ, Yeh WI, Lui MT, Chang KW, Chang CS. 2006. Functional polymorphism in NFKB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers. *Cancer Lett.* 243(1):47-54.

Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, Poulton S, Milstien S, Kohama T, Spiegel S. 2000. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. *J Biol Chem.* 275(26): 19513-20.

Liu HB, Cui NQ, Wang Q, Li DH, Xue XP. 2008. Sphingosine-1-phosphate and its analogue FTY720 diminish acute pulmonary injury in rats with acute necrotizing pancreatitis. *Pancreas.* 36(3):e10-5.

Liu ZM, Chen GG, Ng EK, Leung WK, Sung JJ, Chung SC. 2004. Upregulation of heme oxygenase-1 and p21 confers resistance to apoptosis in human gastric cancer cells. *Oncogene.* 23(2):503-13.

Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2⁻(Delta Delta C(T)) Method. *Methods*. 25(4):402-8.

Lo SS, Lin SC, Wu CW, Chen JH, Yeh WI, Chung MY, Lui WY. 2007. Heme oxygenase-1 gene promoter polymorphism is associated with risk of gastric adenocarcinoma and lymphovascular tumor invasion. *Ann Surg Oncol*.14(8):2250-6.

Lucas da Silva LB, Ribeiro DA, Cury PM, Cordeiro JA, Bueno V. 2008. FTY720 treatment in experimentally urethane-induced lung tumors. *J Exp Ther Oncol*. 7(1):9-15.

Ludwig JA, Weinstein JN. 2005. Biomarkers in cancer staging, prognosis and treatment selection. *Nat Rev Cancer*. 5(11):845-56.

Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S. 2001. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. *Nat Med*. 7(11):1194-201.

Maceyka M, Nava VE, Milstien S, Spiegel S. 2004. Aminoacylase 1 is a sphingosine kinase 1-interacting protein. *FEBS Lett*. 568(1-3):30-4.

Maceyka M, Payne SG, Milstien S, Spiegel S. 2002. Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. *Biochim Biophys Acta*. 1585 (82-3):193-201.

Maines MD, Abrahamsson PA. 1996. Expression of heme oxygenase-1 (HSP32) in human prostate: normal, hyperplastic, and tumor tissue distribution. *Urology*. 47(5):727-33.

Maines MD, Anders MW, Muller-Eberhard U. 1974. Studies on heme transfer from microsomal hemoproteins to heme-binding plasma proteins. *Mol Pharmacol*. 10(2):204-13.

Maines MD, Gibbs PE. 2005. 30 some years of heme oxygenase: from a "molecular wrecking ball" to a "mesmerizing" trigger of cellular events. *Biochem Biophys Res Commun*. 338(1):568-77.

Maines MD, Ibrahim NG, Kappas A. 1977. Solubilization and partial purification of heme oxygenase from rat liver. *J Biol Chem*. 252(16):5900-3.

Maines MD, Trakshel GM, Kutty RK. 1986. Characterization of two constitutive forms of rat liver microsomal heme oxygenase. Only one molecular species of the enzyme is inducible. *J Biol Chem.* 261(1):411-9.

Maines MD. 1988. Heme oxygenase: function. Multiplicity, regulatory mechanisms, and clinical applications. *FASEB J.* 2 (10):2557-68.

Manggau M, Kim DS, Ruwisch L, Vogler R, Korting HC, Schäfer-Korting M, Kleuser B. 2001. 1 α ,25-dihydroxyvitamin D3 protects human keratinocytes from apoptosis by the formation of sphingosine-1-phosphate. *J. Invest. Dermatol.* 117 (5):1241-9.

Marinissen MJ, Tanos T, Bolós M, de Sagarra MR, Coso OA, Cuadrado A. 2006. Inhibition of heme oxygenase-1 interferes with the transforming activity of the Kaposi sarcoma herpesvirus-encoded G protein-coupled receptor. *J Biol Chem.* 281 (16):11332-46.

Mayerhofer M, Florian S, Krauth MT, Aichberger KJ, Bilban M, Marculescu R, Printz D, Fritsch G, Wagner O, Selzer E, Sperr WR, Valent P, Sillaber C. 2004. Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. *Cancer Res.* 64 (9):3148-54.

McAllister SC, Hansen SG, Ruhl RA, Raggo CM, DeFilippis VR, Greenspan D, Früh K, Moses AV. 2004. Kaposi sarcoma-associated herpesvirus (KSHV) induces heme oxygenase-1 expression and activity in KSHV-infected endothelial cells. *Blood.* 103(9):3465-73.

McCoubrey WK Jr, Huang TJ, Maines MD. 1997. Isolation and characterization of a cDNA from the rat brain that encodes hemoprotein heme oxygenase-3. *Eur J Biochem.* 247(2):725-32.

McCoubrey WK Jr, Maines MD. 1994. The structure, organization and differential expression of the gene encoding rat heme oxygenase-2. *Gene.* 139(2):155-61.

McDaid J, Yamashita K, Chora A, Ollinger R, Strom TB, Li XC, Bach FH, Soares MP. 2005. Heme oxygenase-1 modulates the allo-immune response by promoting activation-induced cell death of T cells. *FASEB J.* 19(3):458-60.

Meacci E, Nuti F, Donati C, Cencetti F, Farnararo M, Bruni P. 2008. Sphingosine kinase activity is required for myogenic differentiation of C2C12 myoblasts. *J Cell Physiol.* 214(1):210-20.

Melendez AJ, Carlos-Dias E, Gosink M, Allen JM, Takacs L. 2000. Human sphingosine kinase: molecular cloning, functional characterization and tissue distribution. *Gene.* 251(1):19-26.

Miracca EC, Kowalski LP, Nagai MA. 1999. High prevalence of p16 alterations in head and neck tumours. *Br J Cancer*. 81 (4):677-83.

Miura Y, Yatomi Y, Rile G, Ohmori T, Satoh K, Ozaki Y. 2000. Rho-mediated phosphorylation of focal adhesion kinase and myosin light chain in human endothelial cells stimulated with sphingosine 1-phosphate, a bioactive lysophospholipid released from activated platelets. *J Biochem*. 127(5):909-14.

Moi P, Chan K, Asunis I, Cao A, Kan YW. 1994. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. *Proc Natl Acad Sci U S A*. 91(21):9926-30.

Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS. 2009. Dysregulated molecular networks in head and neck carcinogenesis. *Oral Oncol*. 45(4-5):324-34.

Molinolo AA, Hewitt SM, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses García A, Raimondi AR, Jufe R, Itoiz M, Gao Y, Saranath D, Kaleebi GS, Yoo GH, Leak L, Myers EM, Shintani S, Wong D, Massey HD, Yeudall WA, Lonardo F, Ensley J, Gutkind JS. 2007. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. *Clin Cancer Res*. 13(17):4964-73.

Morse D, Choi AM. 2002. Heme oxygenase-1: the "emerging molecule" has arrived. *Am J Respir Cell Mol Biol*. 27(1):8-16.

Morse D, Choi AM. 2005. Heme oxygenase-1: from bench to bedside. *Am J Respir Crit Care Med*. 172(6):660-70.

Motterlini R, Foresti R, Bassi R, Calabrese V, Clark JE, Green CJ. 2000. Endothelial heme oxygenase-1 induction by hypoxia. Modulation by inducible nitric-oxide synthase and S-nitrosothiols. *J Biol Chem*. 275(18):13613-20.

Mumby S, Upton RL, Chen Y, Stanford SJ, Quinlan GJ, Nicholson AG, Gutteridge JM, Lamb NJ, Evans TW. 2004. Lung heme oxygenase-1 is elevated in acute respiratory distress syndrome. *Crit Care Med*. 32(5):1130-35.

Muppala V, Lin CS, Lee YH. 2000. The role of HNF-1alpha in controlling hepatic catalase activity. *Mol Pharmacol*. 57(1):93-100.

Nagai T, Kikuchi S, Ohmine K, Miyoshi T, Nakamura M, Kondo T, Furuyama K, Komatsu N, Ozawa K. 2008. Hemin reduces cellular sensitivity to imatinib and anthracyclins via Nrf2. *J Cell Biochem*. 104(2):680-91.

Nagiec MM, Skrzypek M, Nagiec EE, Lester RL, Dickson RC. 1998. The LCB4 (YOR171c) and LCB5 (YLR260w) genes of *Saccharomyces* encode sphingoid long chain base kinases. *J Biol Chem*. 273(31):19437-42.

Nava VE, Cuvillier O, Edsall LC, Kimura K, Milstien S, Gelmann EP, Spiegel S. 2000. Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. *Cancer Res*. 60(16):4468-74.

Nemoto S, Nakamura M, Osawa Y, Kono S, Itoh Y, Okano Y, Murate T, Hara A, Ueda H, Nozawa Y, Banno Y. 2009. Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation. *J Biol Chem*. 284:10422-10432.

Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D. 2007. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. *J Clin Invest*. 117(9):2408-21.

Nowis D, Legat M, Grzela T, Niderla J, Wilczek E, Wilczynski GM, Głodkowska E, Mrówka P, Issat T, Dulak J, Józkwicz A, Waś H, Adamek M, Wrzosek A, Nazarewski S, Makowski M, Stokłosa T, Jakóbsiak M, Gołab J. 2006. Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. *Oncogene*. 25(24):3365-74.

Nuhn P, Künzli BM, Hennig R, Mitkus T, Ramanauskas T, Nobiling R, Meuer SC, Friess H, Berberat PO. 2009. Heme oxygenase-1 and its metabolites affect pancreatic tumor growth in vivo. *Mol Cancer*. 8:37.

Obeid LM, Linardic CM, Karolak LA, Hannun YA. 1993. Programed cell death induced by ceramide. *Science*. 259 (5101):1769-71.

Ogretmen B, Hannun YA. 2004. Biologically active sphingolipids in cancer pathogenesis and treatment. *Nat Rev Cancer*. 4 (8):604-16.

Ohata M, Nakamura S, Fujita H, Isemura M. 2005. Prognostic implications of p21 (Waf1/Cip1) immunolocalization in multiple myeloma. *Biomed Res*. 26(3):91-8.

Okamoto I, Krögler J, Endler G, Kaufmann S, Mustafa S, Exner M, Mannhalter C, Wagner O, Pehamberger H. 2006. A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with risk for melanoma. *Int J Cancer*. 119(6):1312-5.

Olivera A, Kohama T, Edsall L, Nava V, Cuvillier O, Poulton S, Spiegel S. 1999. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. *J. Cell Biol.* 147 (3):545-58.

Olivera A, Spiegel S. 1998. Sphingosine kinase. Assay and product analysis. *Methods Mol Biol.* 105:233-42.

Ollinger R, Bilban M, Erat A, Froio A, McDaid J, Tyagi S, Csizmadia E, Graça-Souza AV, Liloia A, Soares MP, Otterbein LE, Usheva A, Yamashita K, Bach FH. 2005. Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation. *Circulation.* 112(7):1030-9.

Opar A. 2008. ASCO presentations highlight value of cancer biomarkers. *Nat Rev Drug Discov.* 7(7):547-8.

Otterbein LE, Bach FH, Alam J, Soares M, Tao Lu H, Wysk M, Davis RJ, Flavell RA, Choi AM. 2000. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. *Nat Med.* 6(4):422-8.

Oyake T, Itoh K, Motohashi H, Hayashi N, Hoshino H, Nishizawa M, Yamamoto M, Igarashi K. 1996. Bach proteins belong to a novel family of BTB-basic leucine zipper transcription factors that interact with MafK and regulate transcription through the NF-E2 site. *Mol Cell Biol.* 16(11):6083-95.

Pae HO, Oh GS, Choi BM, Chae SC, Chung HT. 2003. Differential expressions of heme oxygenase-1 gene in CD25- and CD25+ subsets of human CD4+ T cells. *Biochem Biophys Res Commun.* 306(3):701-5.

Paller MS, Jacob HS. 1994. Cytochrome P-450 mediates tissue-damaging hydroxyl radical formation during reoxygenation of the kidney. *Proc Natl Acad Sci U S A.* 91(15):7002-6.

Park MK, Kang YJ, Ha YM, Jeong JJ, Kim HJ, Seo HG, Lee JH, Chang KC. 2009. EP2 receptor activation by prostaglandin E2 leads to induction of HO-1 via PKA and PI3K pathways in C6 cells. *Biochem Biophys Res Commun.* 379(4):1043-7.

Parkin DM, Bray F, Ferlay J, Pisani P. 2005. Global cancer statistics, 2002. *CA Cancer J Clin.* 55(2), 74-108.

Patwardhan GA, Liu YY. 2011. Sphingolipids and expression regulation of genes in cancer. *Prog Lipid Res.* 50(1):104-14.

Paugh SW, Paugh BS, Rahmani M, Kapitonov D, Almenara JA, Kordula T, Milstien S, Adams JK, Zipkin RE, Grant S, Spiegel S. 2008. A selective

sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. *Blood*. 112(4):1382-91.

Pautas en Oncología. Diagnóstico, tratamiento y seguimiento del cáncer, Instituto de Oncología Ángel H. Roffo, Universidad de Buenos Aires, 2010.

Pchejetski D, Doumerc N, Golzio M, Naymark M, Teissié J, Kohama T, Waxman J, Malavaud B, Cuvillier O. 2008. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. *Mol Cancer Ther*. 7(7):1836-45.

Pitson SM, D'andrea RJ, Vandeleur L, Moretti PA, Xia P, Gamble JR, Vadas MA, Wattenberg BW. 2000. Human sphingosine kinase: purification, molecular cloning and characterization of the native and recombinant enzymes. *Biochem J*. 350 Pt 2:429-41.

Pitson SM, Moretti PA, Zebol JR, Lynn HE, Xia P, Vadas MA, Wattenberg BW. 2003. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. *EMBO J*. 22(20):5491-500.

Pitson SM, Moretti PA, Zebol JR, Zareie R, Derian CK, Darrow AL, Qi J, D'Andrea RJ, Bagley CJ, Vadas MA, Wattenberg BW. 2002. The nucleotide-binding site of human sphingosine kinase 1. *J Biol Chem*. 277(51):49545-53.

Pitson SM, Xia P, Leclercg TM, Moretti PA, Zebol JR, LynnHE, Wattenberg BW, Vadas MA. 2005. Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. *J Exp Med*. 201 (1):49-54.

Policastro L, Molinari B, Larcher F, Blanco P, Podhajcer OL, Costa CS, Rojas P, Durán H. 2004. Imbalance of antioxidant enzymes in tumor cells and inhibition of proliferation and malignant features by scavenging hydrogen peroxide. *Mol Carcinog*. 39(2):103-13.

Pontiggia O, Rodriguez V, Fabris V, Raffo D, Bumashny V, Fiszman G, de Kier Joffé EB, Simian M. 2009. Establishment of an in vitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal-epithelial interactions. *Breast Cancer Res Treat*. 116(2):247-55.

Poss KD, Tonegawa S. 1997. Reduced stress defense in heme oxygenase 1-deficient cells. *Proc Natl Acad Sci U S A*. 94(20):10925-30.

Puglisi F, Di Loreto C, Beltrami CA. 1999. Prognostic-predictive factors and therapeutic choices in invasive carcinoma of the breast. *Ann Ital Chir*. 70(3):335-41.

Radin NS. 2003. Killing tumours by ceramide-induced apoptosis: a critique of available drugs. *Biochem J.* 371 (Pt2):243-56.

Rangarajan A, Weinberg RA. 2003. Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. *Nat Rev Cancer.* 3(12):952-9.

Rapozzi V, Miculan M, Xodo LE. 2009. Evidence that photoactivated pheophorbide a causes in human cancer cells a photodynamic effect involving lipid peroxidation. *Cancer Biol Ther.* 8(14):1318-27.

Reddy K, Cao Y, Zhou Z, Yu L, Jia SF, Kleinerman ES. 2008. VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing's sarcoma vasculature. *Angiogenesis.* 11(3):257-67.

Ren S, Ariga T, Scarsdale JN, Zhang Y, Slominski A, Livingston PO, Ritter G, Kushi Y, Yu RK. 1993. Characterization of a hamster melanoma-associated ganglioside antigen as 7-O-acetylated disialoganglioside GD3. *J Lipid Res.* 34(9):1565-72.

Repine JE, Bast A, Lankhorst I. 1997. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. *Am J Respir Crit Care Med.* 156(2 Pt 1):341-57.

Rhoads AR, Friedberg F. 1997. Sequence motifs for calmodulin recognition. *FASEB J.* 11(5):331-40.

Ricchetti GA, Williams LM, Foxwell BM. 2004. Heme oxygenase 1 expression induced by IL-10 requires STAT-3 and phosphoinositol-3 kinase and is inhibited by lipopolysaccharide. *J Leukoc Biol.* 76(3):719-26.

Rosenwald A, Staudt LM. 2003. Gene expression profiling of diffuse large B-cell lymphoma. *Leuk Lymphoma.* 44 Suppl 3:S41-7.

Ruckhäberle E, Rody A, Engels K, Gaetie R, von Minckwitz G, Schiffmann S, Grösch S, Geisslinger G, Holtrich U, Karn T, Kaufmann M. 2008. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. *Breast Cancer Res. Treat.* 112 (1):41-52.

Saba JD, Hla T. 2004. Point-counterpoint of sphingosine 1-phosphate metabolism. *Circ Res.* 94(6):724-34.

Sabbadini RA. 2011. Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration. *Br J Pharmacol.* 162(6):1225-38.

Sacca P, Meiss R, Casas G, Mazza O, Calvo JC, Navone N, Vazquez E. 2007. Nuclear translocation of haeme oxygenase-1 is associated to prostate cancer. *Br. J. Cancer.* 97 (12):1683-9.

Saddoughi SA, Song P, Ogretmen B. 2008. Roles of bioactive sphingolipids in cancer biology and therapeutics. *Subcell Biochem.* 49:413-40.

Sass G, Leukel P, Schmitz V, Raskopf E, Ocker M, Neureiter D, Meissnitzer M, Tasika E, Tannapfel A, Tiegs G. 2008. Inhibition of heme oxygenase 1 expression by small interfering RNA decreases orthotopic tumor growth in livers of mice. *Int J Cancer.* 123(6):1269-77.

Sassa S, Nagai T. 1996. The role of heme in gene expression. *Int J Hematol.* 63(3):167-78.

Sawa T, Mounawar M, Tatemichi M, Gilibert I, Katoh T, Ohshima H. 2008. Increased risk of gastric cancer in Japanese subjects is associated with microsatellite polymorphisms in the heme oxygenase-1 and the inducible nitric oxide synthase gene promoters. *Cancer Lett.* 269(1):78-84.

Schacter BA, Kurz P. 1982. Alterations in hepatic and splenic microsomal electron transport system components, drug metabolism, heme oxygenase activity, and cytochrome P-450 turnover in Murphy-Sturm lymphosarcoma-bearing rats. *Cancer Res.* 42(9):3557-64.

Schacter BA, Yoda B, Israels LG. 1979. Human spleen heme oxygenase and microsomal electron transport system component activity in normals and in patients with hemolytic anemia, idiopathic thrombocytopenic purpura, and lymphoproliferative disorders. *J Lab Clin Med.* 93(5):838-46.

Schacter BA. 1988. Heme catabolism by heme oxygenase: physiology, regulation, and mechanism of action. *Semin Hematol.* 25(4):349-69.

Schmid G, Guba M, Papyan A, Ischenko I, Brückel M, Bruns CJ, Jauch KW, Graeb C. 2005. FTY720 inhibits tumor growth and angiogenesis. *Transplant Proc.* 37(1):110-1.

Schüppel M, Kürschner U, Kleuser U, Schäfer-Korting M, Kleuser B. 2008. Sphingosine 1-phosphate restrains insulin-mediated keratinocyte proliferation via inhibition of Akt through the S1P2 receptor subtype. *J Invest Dermatol.* 128(7):1747-56.

- Sengupta S, Sellers LA, Matheson HB, Fan TP. 2003. Thymidine phosphorylase induces angiogenesis in vivo and in vitro: an evaluation of possible mechanisms. *Br J Pharmacol.* 139(2):219-31.
- Shi L, Fang J. 2008. Implication of heme oxygenase-1 in the sensitivity of nasopharyngeal carcinomas to radiotherapy. *J Exp Clin Cancer Res.* 27:13.
- Shibahara S, Müller RM, Taguchi H. 1987. Transcriptional control of rat heme oxygenase by heat shock. *J Biol Chem.* 262(27):12889-92.
- Shibahara S, Nakayama M, Kitamuro T, Uono-Fujimori R, Takahashi K. 2003. Repression of heme oxygenase-1 expression as a defense strategy in humans. *Exp Biol Med (Maywood).* 228(5):472-3.
- Shikata Y, Birukov KG, Birukova AA, Verin A, Garcia JG. 2003. Involvement of site-specific FAK phosphorylation in sphingosine-1 phosphate- and thrombin-induced focal adhesion remodeling: role of Src and GIT. *FASEB J.* 17(15):2240-9.
- Shirai K, Kaneshiro T, Wada M, Furuya H, Bielawski J, Hannun YA, Obeid LM, Ogretmen B, Kawamori T. 2011. A role of sphingosine kinase 1 in head and neck carcinogenesis. *Cancer Prev Res (Phila).* 4(3):454-62.
- Siner JM, Jiang G, Cohen ZI, Shan P, Zhang X, Lee CG, Elias JA, Lee PJ. 2007. VEGF-induced heme oxygenase-1 confers cytoprotection from lethal hyperoxia in vivo. *FASEB J.* 21:1422-32.
- Sinha UK, Schorn VJ, Hochstim C, Chinn SB, Zhu S, Masood R. 2011. Increased radiation sensitivity of head and neck squamous cell carcinoma with sphingosine kinase 1 inhibition. *Head Neck.* 33(2):178-88.
- Slebos DJ, Ryter SW, Choi AM. 2003. Heme oxygenase-1 and carbon monoxide in pulmonary medicine. *Respir Res.* 4:7-10.
- Snyder SH, Barañano DE. 2001. Heme oxygenase: a font of multiple messengers. *Neuropsychopharmacology.* 25(3):294-8.
- Sobue S, Nemoto S, Murakami M, Ito H, Kimura A, Gao S, Furuhashi A, Takagi A, Kojima T, Nakamura M, Ito Y, Suzuki M, Banno Y, Nozawa Y, Murate T. 2008. Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukemia cells. *Int J Hematol.* 87(3):266-75.
- Solimini NL, Luo J, Elledge SJ. 2007. Non-oncogene addiction and the stress phenotype of cancer cells. *Cell.* 130(6):986-8.

- Spiegel S, Milstien S. 2007. Functions of the multifaceted family of sphingosine kinases and some close relatives. *J Biol Chem.* 282(4):2125-9.
- Spiegel S. 1999. Sphingosine 1-phosphate: a prototype of a new class of second messengers. *J Leukoc Biol.* 65(3):341-4.
- Staudt LM, Dave S. 2005. The biology of human lymphoid malignancies revealed by gene expression profiling. *Adv Immunol.* 87:163-208.
- Stoffel W, Heimann G, Hellenbroich B. 1973. Sphingosine kinase in blood platelets. *Hoppe Seylers Z Physiol Chem.* 354(5):562-6.
- Struckhoff AP, Patel B, Beckman BS. 2010. Inhibition of p53 sensitizes MCF-7 cells to ceramide treatment. *Int J Oncol.* 37(1): 21-30.
- Stuhlmeier KM. 2000. Activation and regulation of Hsp32 and Hsp70. *Eur J Biochem.* 267(4):1161-7.
- Sugiki H, Hozumi Y, Maeshima H, Katagata Y, Mitsuhashi Y, Kondo S. 2000. C2-ceramide induces apoptosis in a human squamous cell carcinoma cell line. *Br J Dermatol.* 143(6):1154-63.
- Sugiura M, Kono K, Liu H, Shimizugawa T, Minekura H, Spiegel S, Kohama T. 2002. Ceramide kinase, a novel lipid kinase. Molecular cloning and functional characterization. *J Biol Chem.* 277(26):23294-300.
- Sukocheva O, Wadham C, Holmes A, Albanese N, Verrier E, Feng F, Bernal A, Derian CK, Ullrich A, Vadas MA, Xia P. 2006. Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. *J Cell Biol.* 173(2):301-10.
- Sukocheva OA, Wang L, Albanese N, Pitson SM, Vadas MA, Xia P. 2003. Sphingosine kinase transmits estrogen signaling in human breast cancer cells. *Mol Endocrinol.* 17(10):2002-12.
- Sunamura M, Duda DG, Ghattas MH, Lozonschi L, Motoi F, Yamauchi J, Matsuno S, Shibahara S, Abraham NG. 2003. Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. *Angiogenesis.* 6 (1):15-24.
- Sutherland CM, Moretti PA, Hewitt NM, Bagley CJ, Vadas MA, Pitson SM. 2006. The calmodulin-binding site of sphingosine kinase and its role in agonist-dependent translocation of sphingosine kinase 1 to the plasma membrane. *J Biol Chem.* 281 (17):11693-701.
- Sutphen R, Xu Y, Wilbanks GD, Fiorica J, Grendvs EC Jr, LaPolla JP, Arango H, Hoffman MS, Martino M, Wakeley K, Griffin D, Blanco RW, Cantor AB, Xiao

YJ, Krischer JP. 2004. Lysophospholipids are potential biomarkers of ovarian cancer. *Cancer Epidemiol. Biomarkers Prev.* 13 (7): 1185-91.

Suttner DM, Sridhar K, Lee CS, Tomura T, Hansen TN, Dennery PA. 1999. Protective effects of transient HO-1 overexpression on susceptibility to oxygen toxicity in lung cells. *Am J Physiol.* 276 (3 Pt 1):L443-51.

Suzuki H, Riley RT, Sharma RP. 2007. Inducible nitric oxide has protective effect on fumonisin B1 hepatotoxicity in mice via modulation of sphingosine kinase. *Toxicology.* 229(1-2):42-53.

Suzuki H, Tashiro S, Sun J, Doi H, Satomi S, Igarashi K. 2003. Cadmium induces nuclear export of Bach 1, a transcriptional repressor of heme oxygenase-1 gene. *J Biol Chem.* 278 (49):49246-53.

Tacchini L, Dansi P, Matteucci E, Bernelli-Zazzera A, Desiderio MA. 2001. Influence of proteasome and redox state on heat shock-induced activation of stress kinases, AP-1 and HSF. *Biochim Biophys Acta.* 1538(1):76-89.

Taha TA, Hannun YA, Obeid LM. 2006. Sphingosine kinase: biochemical and cellular regulation and role in disease. *J. Biochem. Mol. Biol.* 39 (2):113-31

Taha TA, Osta W, Kozhaya L, Bielawski J, Johnson KR, Gillanders WE, Dbaibo GS, Hannun YA, Obeid LM. 2004. Down-regulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53. *J Biol Chem.* 279 (19):20546-54.

Taketani S, Kohno H, Yoshinaga T, Tokunaga R. 1989. The human 32-kDa stress protein induced by exposure to arsenite and cadmium ions is heme oxygenase. *FEBS Lett.* 245(1-2):173-6.

Tanaka S, Akaike T, Fang J, Beppu T, Ogawa M, Tamura F, Miyamoto Y, Maeda H. 2003. Antiapoptotic effect of haem oxygenase-1 induced by nitric oxide in experimental solid tumour. *Br J Cancer.* 88(6):902-9.

Tenhunen R, Marver HS, Schmid R. 1969. Microsomal heme oxygenase. Characterization of the enzyme. *J Biol Chem.* 244(23):6388-94.

Tenhunen R, Marver HS, Schmid R. 1968. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. *Proc Natl Acad. Sci. U.S.A.* 61 (2):748-55.

Terry CM, Clikeman JA, Hoidal JR, Callahan KS. 1998. Effect of tumor necrosis factor-alpha and interleukin-1 alpha on heme oxygenase-1 expression in human endothelial cells. *Am J Physiol.* 274(3 Pt 2):H883-91.

- Toritsu-Itakura H, Furue M, Kuwano M, Ono M. 2000. Co-expression of thymidine phosphorylase and heme oxygenase-1 in macrophages in human malignant vertical growth melanomas. *Jpn J Cancer Res.* 91(9):906-10.
- Torti FM, Torti SV. 2002. Regulation of ferritin genes and protein. *Blood.* 99(10):3505-16.
- Tsuji MH, Yanagawa T, Iwasa S, Tabuchi K, Onizawa K, Bannai S, Toyooka H, Yoshida H. 1999. Heme oxygenase-1 expression in oral squamous cell carcinoma as involved in lymph node metastasis. *Cancer Lett.* 138 (1-2):53-9.
- Vadas M, Xia P, McCaughan G, Gamble J. 2008. The role of sphingosine kinase 1 in cancer: oncogene or non-oncogene addiction?. *Biochim Biophys Acta.* 1781 (9):442-7.
- Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW. 2005. Sphingosine Kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. *J Neuropathol Exp Neurol.* 64 (8):695-705.
- Van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. 2002. A gene-expression signature as a predictor of survival in breast cancer. *N Engl J Med.* 347(25):1999-2009.
- Vessey DA, Kelley M, Zhang J, Li L, Tao R, Karliner JS. 2007. Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 form of sphingosine kinase from rat heart. *J Biochem Mol Toxicol.* 21(5):273-9.
- Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, Garland WA, Lu Y, Yu S, Hall HS, Kundra V, Mills GB, Sabbadini RA. 2006. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. *Cancer Cell.* 9(3):225-38.
- Vogler R, Sauer B, Kim DS, Schäfer-Korting M, Kleuser B. 2003. Sphingosine-1-phosphate and its potentially paradoxical effects on critical parameters of cutaneous wound healing. *J Invest Dermatol.* 120 (4):693-700.
- Walker MR, Kasprovicz DJ, Gersuk VH, Benard A, Van Landeghen M, Buckner JH, Ziegler SF. 2003. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. *J Clin Invest.* 112(9):1437-43.
- Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D,

Foekens JA. 2005. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. *Lancet* 365(9460):671–79.

Was H, Cichon T, Smolarczyk R, Rudnicka D, Stopa M, Chevalier C, Leger JJ, Lackowska B, Grochot A, Bojkowska K, Ratajska A, Kieda C, Szala S, Dulak J, Jozkowicz A. 2006. Overexpression of heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice. *Am J Pathol.* 169 (6):2181-98.

Was H, Dulak J, Jozkowicz A. 2010. Heme oxygenase-1 in tumor biology and therapy. *Curr Drug Targets.* 11(12):1551-70.

Was H, Sokolowska M, Sierpniowska A, Dominik P, Skrzypek K, Lackowska B, Pratkanicki A, Grochot-Przeczek A, Taha H, Kotlinowski J, Kozakowska M, Mazan A, Nowak W, Muchova L, Vitek L, Ratajska A, Dulak J, Jozkowicz A. 2011. Effects of heme oxygenase-1 on induction and development of chemically induced squamous cell carcinoma in mice. *Free Radic Biol Med.* 51(9):1717-26.

Weis N, Weigert A, von Knethen A, Brüne B. 2009. Heme oxygenase-1 contributes to an alternative macrophage activation profile induced by apoptotic cell supernatants. *Mol Biol Cell.* 20(5):1280-8.

Wise CD, Drabkin DL. 1964. Degradation of haemoglobin and hemin to biliverdin by a new cell-free system obtained from hemophagous organ of dog placenta. *Fed Proc.* 23:323.

Xia P, Gamble JR, Wang L, Pitson SM, Moretti PA, Wattenberg BW, D'Andrea RJ, Vadas MA. 2000. An oncogenic role of sphingosine kinase. *Curr Biol.* 10(23): 1527-30.

Xia P, Wang L, Gamble JR, Vadas MA. 1999. Activation of sphingosine kinase by tumor necrosis factor-alpha inhibits apoptosis in human endothelial cells. *J Biol Chem.* 274(48):34499-505.

Xia P, Wang L, Moretti PA, Albanese N, Chai F, Pitson SM, D'Andrea RJ, Gamble JR, Vadas MA. 2002. Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling. *J. Biol. Chem.* 277 (10):7996-8003.

Xie X, Clausen OP, Boysen M. 2002. Prognostic significance of p21WAF1/CIP1 expression in tongue squamous cell carcinomas. *Arch Otolaryngol Head Neck Surg.* 128 (8):897-902.

Yachie A, Niida Y, Wada T, Igarashi N, Kaneda H, Toma T, Ohta K, Kasahara Y, Koizumi S. 1999. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. *J Clin Invest.* 103(1):129-35.

Yamashita K, Ollinger R, McDaid J, Sakahama H, Wang H, Tyagi S, Csizmadia E, Smith NR, Soares MP, Bach FH. 2006. Heme oxygenase-1 is essential for and promotes tolerance to transplanted organs. *FASEB J.* 20(6):776-8.

Yanagawa T, Omura K, Harada H, Nakaso K, Iwasa S, Koyama Y, Onizawa K, Yusa H, Yoshida H. 2004. Heme oxygenase-1 expression predicts cervical lymph node metastasis of tongue squamous cell carcinomas. *Oral Oncol.* 40(1):21-7.

Yatomi Y, Igarashi Y, Yang L, Hisano N, Qi R, Asazuma N, Satoh K, Ozaki Y, Kume S. 1997. Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. *J Biochem.* 121(5):969-73.

Yim MS, Ha YS, Kim IY, Yun SJ, Choi YH, Kim WJ. 2011. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression. *J Urol.*;185(2):701-5.

Yokota S, Taniguchi Y, Kihara A, Mitsutake S, Igarashi Y. 2004. Asp177 in C4 domain of mouse sphingosine kinase 1a is important for the sphingosine recognition. *FEBS Lett.* 578, 106-110.

Yoshida T, Kikuchi G. 1978. Purification and properties of heme oxygenase from pig spleen microsomes. *J Biol Chem.* 253(12):4224-9.

Yoshinaga T, Sassa S, Kappas A. 1982. A comparative study of heme degradation by NADPH-cytochrome c reductase alone and by the complete heme oxygenase system. Distinctive aspects of heme degradation by NADPH-cytochrome c reductase. *J Biol Chem.* 257 (13):7794-802.

Yu H, Chen JK, Feng S, Dalgarno DC, Brauer AW, Schreiber S. L. 1994. Structural basis for the binding of proline-rich peptides to SH3 domains. *Cell* 76, 933-45.

Zhang H, Desai NN, Olivera, A, Seki T, Brooker G, Spiegel S. 1991. Sphingosine- 1-phosphate, a novel lipid, involved in cellular proliferation. *J. Cell Biol.*, 114:155–67.

Zhang WL, Tsuneishi S, Nakamura H. 2001. Induction of heat shock proteins and its effects on glial differentiation in rat C6 glioblastoma cells. *Kobe J Med Sci.* 47(2):77-95.

Zhou H, Lu F, Latham C, Zander DS, Visner GA. 2004. Heme oxygenase-1 expression in human lungs with cystic fibrosis and cytoprotective effects against *Pseudomonas aeruginosa* in vitro. *Am J Respir Crit Care Med.* 170(6):633-40.